Loading...

Faes Farma

DB:FFEA
Snowflake Description

Flawless balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FFEA
DB
€1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials. The last earnings update was 21 days ago. More info.


Add to Portfolio Compare Print
FFEA Share Price and Events
7 Day Returns
-2.4%
DB:FFEA
-2.6%
DE Pharmaceuticals
-0.2%
DE Market
1 Year Returns
13.4%
DB:FFEA
-28.9%
DE Pharmaceuticals
-10.3%
DE Market
FFEA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Faes Farma (FFEA) -2.4% 1.2% 21% 13.4% 41.1% 88.8%
DE Pharmaceuticals -2.6% -4.6% -10.2% -28.9% -20.1% 5.5%
DE Market -0.2% -2.4% 4% -10.3% 11.2% 10.8%
1 Year Return vs Industry and Market
  • FFEA outperformed the Pharmaceuticals industry which returned -28.9% over the past year.
  • FFEA outperformed the Market in Germany which returned -10.3% over the past year.
Price Volatility
FFEA
Industry
5yr Volatility vs Market

FFEA Value

 Is Faes Farma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Faes Farma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Faes Farma.

DB:FFEA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:FFEA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 8.2%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.695 (1 + (1- 25%) (5.06%))
0.813
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.813 * 8.18%)
6.88%

Discounted Cash Flow Calculation for DB:FFEA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Faes Farma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:FFEA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.88%)
2019 42.90 Analyst x1 40.14
2020 56.07 Analyst x3 49.08
2021 67.00 Analyst x1 54.88
2022 74.05 Est @ 10.53% 56.75
2023 79.56 Est @ 7.44% 57.05
2024 83.76 Est @ 5.27% 56.19
2025 86.91 Est @ 3.76% 54.55
2026 89.26 Est @ 2.7% 52.42
2027 91.00 Est @ 1.96% 50.00
2028 92.31 Est @ 1.44% 47.46
Present value of next 10 years cash flows €518.52
DB:FFEA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €92.31 × (1 + 0.23%) ÷ (6.88% – 0.23%)
€1,391.02
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €1,391.02 ÷ (1 + 6.88%)10
€715.14
DB:FFEA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €518.52 + €715.14
€1,233.65
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €1,233.65 / 274.08
€4.5
DB:FFEA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:FFEA represents 0.97273x of BME:FAE
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.97273x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 4.50 x 0.97273
€4.38
Value per share (EUR) From above. €4.38
Current discount Discount to share price of €3.93
= -1 x (€3.93 - €4.38) / €4.38
10.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Faes Farma is available for.
Intrinsic value
10%
Share price is €3.93 vs Future cash flow value of €4.38
Current Discount Checks
For Faes Farma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Faes Farma's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Faes Farma's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Faes Farma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Faes Farma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:FFEA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in EUR €0.20
BME:FAE Share Price ** BME (2019-05-20) in EUR €4.04
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.4x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Faes Farma.

DB:FFEA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BME:FAE Share Price ÷ EPS (both in EUR)

= 4.04 ÷ 0.20

19.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Faes Farma is good value based on earnings compared to the DE Pharmaceuticals industry average.
  • Faes Farma is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Faes Farma's expected growth come at a high price?
Raw Data
DB:FFEA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 19.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
10.8%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.93x
Germany Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

DB:FFEA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 19.8x ÷ 10.8%

1.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Faes Farma is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Faes Farma's assets?
Raw Data
DB:FFEA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in EUR €1.35
BME:FAE Share Price * BME (2019-05-20) in EUR €4.04
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.3x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.78x
DB:FFEA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BME:FAE Share Price ÷ Book Value per Share (both in EUR)

= 4.04 ÷ 1.35

2.98x

* Primary Listing of Faes Farma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Faes Farma is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Faes Farma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Faes Farma has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

FFEA Future Performance

 How is Faes Farma expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Faes Farma expected to grow at an attractive rate?
  • Faes Farma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Faes Farma's earnings growth is positive but not above the Germany market average.
  • Faes Farma's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:FFEA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:FFEA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 10.8%
DB:FFEA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 3.1%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17.9%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:FFEA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:FFEA Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 87
2022-12-31 91
2021-12-31 381 84 75 1
2020-12-31 369 74 68 2
2019-12-31 355 64 60 1
DB:FFEA Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-03-31 351 54
2018-12-31 340 59 52
2018-09-30 334 51
2018-06-30 330 58 50
2018-03-31 308 47
2017-12-31 282 42 41
2017-09-30 266 39
2017-06-30 250 43 39
2017-03-31 241 38
2016-12-31 237 50 37
2016-09-30 226 35
2016-06-30 222 40 34

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Faes Farma's earnings are expected to grow by 10.8% yearly, however this is not considered high growth (20% yearly).
  • Faes Farma's revenue is expected to grow by 3.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:FFEA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Faes Farma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:FFEA Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.26 0.27 0.24 2.00
2020-12-31 0.24 0.26 0.23 3.00
2019-12-31 0.22 0.23 0.21 3.00
DB:FFEA Past Financials Data
Date (Data in EUR Millions) EPS *
2019-03-31 0.20
2018-12-31 0.19
2018-09-30
2018-06-30 0.19
2018-03-31
2017-12-31 0.16
2017-09-30
2017-06-30 0.15
2017-03-31
2016-12-31 0.15
2016-09-30
2016-06-30 0.13

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Faes Farma is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Faes Farma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Faes Farma has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

FFEA Past Performance

  How has Faes Farma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Faes Farma's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Faes Farma's year on year earnings growth rate has been positive over the past 5 years.
  • Faes Farma's 1-year earnings growth is less than its 5-year average (16.5% vs 18.2%)
  • Faes Farma's earnings growth has not exceeded the DE Pharmaceuticals industry average in the past year (16.5% vs 25.7%).
Earnings and Revenue History
Faes Farma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Faes Farma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:FFEA Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 351.12 54.21 94.98
2018-12-31 339.92 51.59 94.21
2018-09-30 333.66 51.22 86.62
2018-06-30 329.75 50.06 85.65
2018-03-31 307.56 46.52 80.92
2017-12-31 282.16 41.38 77.02
2017-09-30 265.76 39.19 69.86
2017-06-30 250.40 39.08 66.76
2017-03-31 240.66 37.79 66.26
2016-12-31 236.86 36.59 65.66
2016-09-30 225.84 35.16 63.70
2016-06-30 222.11 33.50 63.03
2016-03-31 219.84 31.66 62.40
2015-12-31 214.24 30.36 60.80
2015-09-30 207.39 28.43 58.83 0.67
2015-06-30 202.86 26.85 57.57
2015-03-31 195.91 26.43 45.18
2014-12-31 198.06 25.33 57.57
2014-09-30 194.67 23.49 60.40 1.38
2014-06-30 193.98 23.95 59.53 1.38
2014-03-31 191.71 20.47 60.40 1.38
2013-12-31 193.32 22.61 60.40 1.38
2013-09-30 195.89 21.50 64.93 1.38
2013-06-30 196.89 22.91 64.55 0.92
2013-03-31 190.97 21.12 64.93 1.38
2012-12-31 189.88 19.52 64.93 1.38
2012-09-30 185.43 18.96 67.11 1.36
2012-06-30 179.72 13.08 67.88 1.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Faes Farma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Faes Farma used its assets more efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.
  • Faes Farma has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Faes Farma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Faes Farma has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

FFEA Health

 How is Faes Farma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Faes Farma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Faes Farma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Faes Farma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Faes Farma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Faes Farma Company Filings, last reported 1 month ago.

DB:FFEA Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 360.15 56.00 76.41
2018-12-31 360.15 56.00 76.41
2018-09-30 343.90 52.87 57.55
2018-06-30 343.90 52.87 57.55
2018-03-31 320.78 52.13 43.34
2017-12-31 320.04 52.13 43.34
2017-09-30 302.25 55.69 31.28
2017-06-30 302.25 55.69 31.28
2017-03-31 284.89 0.00 66.01
2016-12-31 284.89 3.49 66.01
2016-09-30 268.52 0.00 41.67
2016-06-30 268.52 0.00 41.67
2016-03-31 254.34 0.00 32.91
2015-12-31 254.34 0.00 32.91
2015-09-30 240.62 3.04 18.94
2015-06-30 240.62 3.04 18.94
2015-03-31 228.63 7.37 13.28
2014-12-31 228.63 7.37 13.28
2014-09-30 218.80 32.99 15.31
2014-06-30 218.80 32.99 15.31
2014-03-31 197.81 33.96 14.73
2013-12-31 197.81 33.96 14.73
2013-09-30 196.97 57.17 24.04
2013-06-30 196.97 57.17 24.04
2013-03-31 184.82 59.98 10.63
2012-12-31 184.82 57.74 10.58
2012-09-30 174.88 78.18 17.00
2012-06-30 174.88 78.18 17.00
  • Faes Farma's level of debt (15.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (17.1% vs 15.5% today).
  • Debt is well covered by operating cash flow (106%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 402.3x coverage).
X
Financial health checks
We assess Faes Farma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Faes Farma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

FFEA Dividends

 What is Faes Farma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.55%
Current annual income from Faes Farma dividends. Estimated to be 1.59% next year.
If you bought €2,000 of Faes Farma shares you are expected to receive €11 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Faes Farma's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.45%).
  • Faes Farma's dividend is below the markets top 25% of dividend payers in Germany (3.81%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:FFEA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:FFEA Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.10 2.00
2020-12-31 0.05 2.00
2019-12-31 0.03 1.00
DB:FFEA Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-04-29 0.022 0.546
2019-02-28 0.022 0.599
2018-07-27 0.020 0.574
2018-03-01 0.020 0.596
2018-02-28 0.020 0.729
2017-07-24 0.018 0.631
2017-02-28 0.018 0.572
2016-02-25 0.017 0.524
2015-10-29 0.080 3.065
2015-06-19 0.080 3.289
2011-07-29 0.069 5.408
2011-05-12 0.069 3.600
2011-05-09 0.069 3.064
2010-11-08 0.057 2.369
2010-06-23 0.072 2.910
2010-02-24 0.064 2.360
2009-10-29 0.052 1.762
2009-07-30 0.072 2.282

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Faes Farma is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • Faes Farma is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Faes Farma's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Faes Farma's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (4.2x coverage).
X
Income/ dividend checks
We assess Faes Farma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Faes Farma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Faes Farma has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

FFEA Management

 What is the CEO of Faes Farma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Faes Farma has no CEO, or we have no data on them.
Management Team

Mariano Ucar Angulo

TITLE
Chairman of the Board of Directors
COMPENSATION
€919K

Gonzalo Fernández de Valderrama Iribarnegaray

TITLE
Secretary of The Board of Directors
COMPENSATION
€108K
TENURE
10.9 yrs

Belén Amatriain Corbi

TITLE
Independent Director
AGE
59
Board of Directors Tenure

Average tenure of the Faes Farma board of directors in years:

5.9
Average Tenure
  • The tenure for the Faes Farma board of directors is about average.
Board of Directors

Mariano Ucar Angulo

TITLE
Chairman of the Board of Directors
COMPENSATION
€919K
TENURE
5.9 yrs

Eduardo Fernández de Valderrama y Murillo

TITLE
Director
COMPENSATION
€60K
TENURE
5.9 yrs

Iñigo Ortiz de la Torre

TITLE
Director
COMPENSATION
€63K
TENURE
24.9 yrs

Carmen Basagoiti Pastor

TITLE
Director
COMPENSATION
€57K
TENURE
6.9 yrs

Carmelo de las Morenas López

TITLE
Director
COMPENSATION
€66K
TENURE
11.9 yrs

Francisco Javier de Usaola García

TITLE
Director
COMPENSATION
€57K
TENURE
5.9 yrs

Ignacio Garralda de Velasco Consejero

TITLE
Director
COMPENSATION
€57K
AGE
67

Carlos de Alcocer Torra

TITLE
Director
COMPENSATION
€64K
TENURE
5.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
10. Sep 18 Buy Iñigo Ortiz de la Torre Individual 07. Sep 18 07. Sep 18 3,000 €3.62 €10,860
26. Jun 18 Buy Carlos de Alcocer Torra Individual 22. Jun 18 22. Jun 18 10,361 €3.55 €36,782
22. Jun 18 Buy Carmen Basagoiti Pastor Individual 19. Jun 18 19. Jun 18 849 €3.54 €3,005
22. May 18 Buy Mariano Ucar Angulo Individual 21. May 18 21. May 18 30,000 €3.46 €103,800
X
Management checks
We assess Faes Farma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Faes Farma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

FFEA News

Simply Wall St News

FFEA Company Info

Description

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Colme to treat chronic alcoholism; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. In addition, it offers sitagliptine, and sitagliptine and metformine products to treat diabetes type-II; Hidroferol; Acoxxel; Pankreoflat, an OTC products; Hemorrance for the treatment of haemorrhoids; and respiratory products, as well as ProFaes4 Adultos, Digest, Viajeros, Edad Escolar, and Dual Vit. Further, the company provides Diosmin and Micronized Diosmin for chronic venous insufficiency; Sulbutiamine to treat asthenia, concentration, and memory deficit; Arginine Aspartate for the treatment of erectile dysfunction; swine feeding and nutrition products; and products and services for the animal nutrition industry. It operates in approximately 60 countries in Latin America, Africa, the Middle East, Asia, and Europe. Faes Farma, S.A. was founded in 1933 and is headquartered in Madrid, Spain.

Details
Name: Faes Farma, S.A.
FFEA
Exchange: DB
Founded: 1933
€1,105,900,303
274,076,903
Website: http://faesfarma.com
Address: Faes Farma, S.A.
Parque empresarial "Cristalia" Calle Vía de los Poblados 3,
Edificio 2, 2º Izquierda (Hortaleza),
Madrid,
Madrid, 28033,
Spain
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BME FAE Ordinary Shares Bolsas y Mercados Espanoles ES EUR 20. Oct 1989
DB FFEA Ordinary Shares Deutsche Boerse AG DE EUR 20. Oct 1989
LSE 0K9H Ordinary Shares London Stock Exchange GB EUR 20. Oct 1989
BATS-CHIXE FAEE Ordinary Shares BATS 'Chi-X Europe' GB EUR 20. Oct 1989
Number of employees
Current staff
Staff numbers
1,111
Faes Farma employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 21:15
End of day share price update: 2019/05/20 00:00
Last estimates confirmation: 2019/05/16
Last earnings filing: 2019/04/29
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.